Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
NextCure, Inc. - Common Stock
(NQ:
NXTC
)
0.9688
-0.0012 (-0.12%)
Streaming Delayed Price
Updated: 10:10 AM EST, Dec 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about NextCure, Inc. - Common Stock
< Previous
1
2
Next >
NextCure Announces Acceptance of IND Application for LNCB74
December 10, 2024
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences
From
NextCure
Via
GlobeNewswire
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
November 26, 2024
From
NextCure
Via
GlobeNewswire
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
November 19, 2024
From
NextCure
Via
GlobeNewswire
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
November 07, 2024
From
NextCure
Via
GlobeNewswire
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
November 05, 2024
From
NextCure
Via
GlobeNewswire
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
October 04, 2024
From
NextCure
Via
GlobeNewswire
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
September 16, 2024
From
NextCure
Via
GlobeNewswire
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
August 01, 2024
From
NextCure
Via
GlobeNewswire
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 20, 2024
From
NextCure
Via
GlobeNewswire
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
May 30, 2024
From
NextCure
Via
GlobeNewswire
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
May 02, 2024
From
NextCure
Via
GlobeNewswire
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
April 24, 2024
From
NextCure
Via
GlobeNewswire
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
April 08, 2024
Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74
From
NextCure
Via
GlobeNewswire
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
April 04, 2024
From
NextCure
Via
GlobeNewswire
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
NextCure
Via
GlobeNewswire
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
March 21, 2024
From
NextCure
Via
GlobeNewswire
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
March 05, 2024
From
NextCure
Via
GlobeNewswire
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
January 18, 2024
From
NextCure
Via
GlobeNewswire
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
December 21, 2023
From
NextCure
Via
GlobeNewswire
NextCure Provides Year-End Clinical Pipeline Updates
December 14, 2023
From
NextCure
Via
GlobeNewswire
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
November 20, 2023
From
NextCure
Via
GlobeNewswire
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
November 15, 2023
From
NextCure
Via
GlobeNewswire
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
November 02, 2023
From
NextCure
Via
GlobeNewswire
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
October 17, 2023
Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting
From
NextCure
Via
GlobeNewswire
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease
September 26, 2023
From
NextCure
Via
GlobeNewswire
A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
September 12, 2023
From
NextCure
Via
GlobeNewswire
NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen
September 07, 2023
From
NextCure
Via
GlobeNewswire
Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease
September 05, 2023
From
NextCure
Via
GlobeNewswire
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 31, 2023
From
NextCure
Via
GlobeNewswire
NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results
August 03, 2023
From
NextCure
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.